{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:00:17Z","timestamp":1782360017543,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Anhui Province Scientific Research Project","award":["AHWJ2023BAc10031"],"award-info":[{"award-number":["AHWJ2023BAc10031"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["WK9110000172"],"award-info":[{"award-number":["WK9110000172"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14207-8","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:26:23Z","timestamp":1746771983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Shusheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"14207_CR1","doi-asserted-by":"crossref","unstructured":"Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current Status and Future Prospects for Esophageal Cancer. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030765"},{"issue":"1","key":"14207_CR2","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.esmoop.2023.100789","volume":"8","author":"HC Puhr","year":"2023","unstructured":"Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789.","journal-title":"ESMO Open"},{"issue":"3","key":"14207_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163(3):649\u201358. e2.","journal-title":"Gastroenterology"},{"issue":"11","key":"14207_CR4","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.apsb.2021.03.008","volume":"11","author":"S He","year":"2021","unstructured":"He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021;11(11):3379\u201392.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"14207_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","volume":"5","author":"YM Yang","year":"2020","unstructured":"Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):229.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"14207_CR6","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1097\/CM9.0000000000002768","volume":"136","author":"H Yang","year":"2023","unstructured":"Yang H, Li X, Yang W. Advances in targeted therapy and immunotherapy for esophageal cancer. Chin Med J (Engl). 2023;136(16):1910\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"14207_CR7","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.2147\/DDDT.S97235","volume":"9","author":"H Zhang","year":"2015","unstructured":"Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075\u201381.","journal-title":"Drug Des Devel Ther"},{"key":"14207_CR8","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.2147\/OTT.S132756","volume":"10","author":"J Li","year":"2017","unstructured":"Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. OncoTargets therapy. 2017;10:3965\u201369.","journal-title":"OncoTargets therapy"},{"issue":"2","key":"14207_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10637-019-00866-5","volume":"38","author":"J Zhao","year":"2020","unstructured":"Zhao J, Lei J, Yu J, Zhang C, Song X, Zhang N, Wang Y, Zhang S. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. Invest New Drugs. 2020;38(2):500\u201306.","journal-title":"Invest New Drugs"},{"issue":"6","key":"14207_CR10","doi-asserted-by":"publisher","first-page":"e925","DOI":"10.1002\/onco.13668","volume":"26","author":"L Chu","year":"2021","unstructured":"Chu L, Chen Y, Liu Q, Liang F, Wang S, Liu Q, Yu H, Wu X, Zhang J, Deng J, et al. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11). Oncologist. 2021;26(6):e925\u201335.","journal-title":"Oncologist"},{"key":"14207_CR11","doi-asserted-by":"publisher","first-page":"937307","DOI":"10.3389\/fimmu.2022.937307","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Huang H, Zhang T, Feng H, Wang S, Zhang Y, Ji X, Cheng X, Zhao R. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. Front Immunol. 2022;13:937307.","journal-title":"Front Immunol"},{"issue":"9","key":"14207_CR12","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/cas.14541","volume":"111","author":"Y Baba","year":"2020","unstructured":"Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Baba H. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3132\u201341.","journal-title":"Cancer Sci"},{"issue":"12","key":"14207_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cac2.12119","volume":"40","author":"B Zhang","year":"2020","unstructured":"Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, Wang X, Bai L, Huang J. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond). 2020;40(12):711\u201320.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"14207_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.21037\/tlcr-23-60","volume":"12","author":"AM Wilk","year":"2023","unstructured":"Wilk AM, Kozlowska E, Borys D, D\u2019Amico A, Fujarewicz K, Gorczewska I, Debosz-Suwinska I, Suwinski R, Smieja J, Swierniak A. Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer. Transl Lung Cancer Res. 2023;12(7):1372\u201383.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"14207_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-024-11917-3","volume":"24","author":"H Liu","year":"2024","unstructured":"Liu H, Cui Y, Chang C, Zhou Z, Zhang Y, Ma C, Yin Y, Wang R. Development and validation of a (18)F-FDG PET\/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study. BMC Cancer. 2024;24(1):150.","journal-title":"BMC Cancer"},{"issue":"1","key":"14207_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13014-022-02186-0","volume":"17","author":"Y Cui","year":"2022","unstructured":"Cui Y, Li Z, Xiang M, Han D, Yin Y, Ma C. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures. Radiat Oncol. 2022;17(1):212.","journal-title":"Radiat Oncol"},{"issue":"3","key":"14207_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","volume":"7","author":"X Meng","year":"2022","unstructured":"Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):245\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"14207_CR18","doi-asserted-by":"publisher","first-page":"114328","DOI":"10.1016\/j.ejca.2024.114328","volume":"212","author":"X Meng","year":"2024","unstructured":"Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, Lu P, Guo Y, Ji Y, Zhang M, et al. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024;212:114328.","journal-title":"Eur J Cancer"},{"issue":"26","key":"14207_CR19","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin oncology: official J Am Soc Clin Oncol. 2022;40(26):3065\u201376.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"6","key":"14207_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"11","key":"14207_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"Pt B","key":"14207_CR22","doi-asserted-by":"publisher","first-page":"111147","DOI":"10.1016\/j.intimp.2023.111147","volume":"125","author":"Y Yao","year":"2023","unstructured":"Yao Y, Wang Y, Du Y, Jiang F, Liang H, Bi M, Xie H, Peng W, Pan Y. Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study. Int Immunopharmacol. 2023;125(Pt B):111147.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"14207_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021;27(4):1003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"14207_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21037\/atm-21-4792","volume":"10","author":"G Gao","year":"2022","unstructured":"Gao G, Zhao J, Ren S, Wang Y, Chen G, Chen J, Gu K, Guo R, Pan Y, Wang Q, et al. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. Ann Transl Med. 2022;10(8):441.","journal-title":"Ann Transl Med"},{"issue":"11","key":"14207_CR25","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00262-022-03174-9","volume":"71","author":"C Jing","year":"2022","unstructured":"Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, et al. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunol Immunother. 2022;71(11):2597\u2013608.","journal-title":"Cancer Immunol Immunother"},{"key":"14207_CR26","doi-asserted-by":"crossref","unstructured":"Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib\/II trial. J Immunother Cancer. 2021;9(3).","DOI":"10.1136\/jitc-2020-002191"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14207-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:26:27Z","timestamp":1746771987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14207"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14207-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of the First Affiliated Hospital of USTC West District (Approval Number: Lunshen 2019 No. 24) and was prospectively registered in the China Clinical Trial Registry (ChiCTR2000028857) on January 5, 2020. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"845"}}